Travere Therapeutics (TVTX) Current Assets (2012 - 2026)
Travere Therapeutics' (TVTX) quarterly Current Assets came in at $392.7 million in Q1 2026, up 4.95% YoY from $374.2 million in Q1 2025, and down 10.26% on a QoQ basis from $437.6 million in Q4 2025.
Travere Therapeutics (TVTX) Current Assets (2012 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 15 years of Current Assets data on file, last reported at $392.7 million in Q1 2026.
- Quarterly Current Assets rose 4.95% year-over-year to $392.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $392.7 million (up 4.95% YoY) and the FY2025 annual result came in at $437.6 million, up 5.01% from the prior year.
- Current Assets eased to $392.7 million in Q1 2026, from $437.6 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $686.2 million in Q3 2023 to a low of $324.7 million in Q3 2024.
- A 5-year average of $484.5 million and a median of $481.1 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets rose 28.31% — and 2024, when it slumped 52.68%.
- Tracing TVTX's Current Assets over 5 years: stood at $486.4 million in 2022, then rose by 26.79% to $616.8 million in 2023, then plunged by 32.44% to $416.7 million in 2024, then gained by 5.01% to $437.6 million in 2025, then retreated by 10.26% to $392.7 million in 2026.
- The last three Current Assets figures came in at $392.7 million (Q1 2026), $437.6 million (Q4 2025), and $371.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 615.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 615.14 Mn |
| Mar 31, 2026 | 392.68 Mn |
| Dec 31, 2025 | 437.57 Mn |
| Sep 30, 2025 | 371.11 Mn |
| Jun 30, 2025 | 379.57 Mn |
| Mar 31, 2025 | 374.17 Mn |
| Dec 31, 2024 | 416.70 Mn |
| Sep 30, 2024 | 324.74 Mn |
| Jun 30, 2024 | 368.98 Mn |
| Mar 31, 2024 | 481.08 Mn |
| Dec 31, 2023 | 616.78 Mn |
| Sep 30, 2023 | 686.23 Mn |
| Jun 30, 2023 | 542.06 Mn |
| Mar 31, 2023 | 604.90 Mn |
| Dec 31, 2022 | 486.44 Mn |
| Sep 30, 2022 | 534.84 Mn |
| Jun 30, 2022 | 586.78 Mn |
| Mar 31, 2022 | 631.09 Mn |
| Dec 31, 2021 | 582.83 Mn |
| Sep 30, 2021 | 579.08 Mn |